董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paula Brown Stafford | 女 | President, Chief Executive Officer, Director and Chairman of the Board | 57 | 112.88万美元 | 未持股 | 2021-03-22 |
| Steven D. Skolsky | 男 | Director | 65 | 未披露 | 未持股 | 2021-03-22 |
| W. Kent Geer | 男 | Director | 66 | 未披露 | 未持股 | 2021-03-22 |
| John Palmour | 男 | Director | 60 | 7.32万美元 | 未持股 | 2021-03-22 |
| Machelle Sanders | 女 | Director | 57 | 6.69万美元 | 未持股 | 2021-03-22 |
| James L. Bierman | 男 | Director | 68 | 1.95万美元 | 未持股 | 2021-03-22 |
| James L. Bierman | 男 | Director | 68 | 未披露 | 未持股 | 2021-03-22 |
| Robert J. Keegan | 男 | Director | 73 | 8.64万美元 | 未持股 | 2021-03-22 |
| W. Kent Geer | 男 | Director | 66 | 11.04万美元 | 未持股 | 2021-03-22 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paula Brown Stafford | 女 | President, Chief Executive Officer, Director and Chairman of the Board | 57 | 112.88万美元 | 未持股 | 2021-03-22 |
| John M. Gay | 男 | Chief Financial Officer | 44 | 41.79万美元 | 未持股 | 2021-03-22 |
董事简历
中英对照 | 中文 | 英文- Paula Brown Stafford
-
Paula Brown Stafford，她是Novan, Inc.的总裁兼首席执行官，并于2020年7月28日被任命为董事长。Stafford女士自2019年1月起担任Novan, Inc.的总裁。在她被任命为Novan, Inc.从2017年3月到2019年1月，她担任Novan, Inc.的首席发展官。她一直担任Novan, Inc.的董事（2017年8月以来）。加入Novan之前，她曾在IQVIA Holdings Inc.（生物制药开发服务和商业外包服务的领先跨国供应商）担任各种越来越重要的职务。自1985年以来，她担任临床开发总裁（从2010年到2015年），负责全球所有I-IV期临床开发业务，并在Quintiles执行委员会任职。她还担任Health Decisions的董事，这是一个全面服务合同研究组织，专门从事妇女健康适应症治疗的临床研究。她还担任the Gillings School of Global Public Health at the University of North Carolina, Chapel Hill的公共卫生领导兼职教授。经营着自己的第三方咨询业务。
Paula Brown Stafford is Novan, Inc. President and Chief Executive Officer and was appointed as Chairman of Novan, Inc. of directors effective July 28 2020. Ms. Stafford has served as Novan, Inc. President since January 2019. Prior to her appointment as Novan, Inc. Chief Executive Officer effective February 2 2020 Ms. Stafford served as our Chief Operating Officer from January 2019 to February 2020 after serving as Novan, Inc. Chief Development Officer from March 2017 to January 2019. Ms. Stafford has served as a member of Novan, Inc. of directors since August 2017. Prior to joining Novan, Ms. Stafford held various roles of increasing importance at Quintiles Transnational Holdings Inc. now IQVIA Holdings Inc., a leading multinational provider of biopharmaceutical development services and commercial outsourcing services, since 1985 including serving as President of Clinical Development from 2010 to 2015 where she was responsible for all Phase I-IV clinical development operations globally and served on the Quintiles Executive Committee. Ms. Stafford also serves as a director of Health Decisions, a full-service contract research organization specializing in clinical studies of therapeutics for women's health indications, serves as an adjunct professor in Public Health Leadership at the Gillings School of Global Public Health at the University of North Carolina, Chapel Hill, and operates her own third-party consulting business. - Paula Brown Stafford，她是Novan, Inc.的总裁兼首席执行官，并于2020年7月28日被任命为董事长。Stafford女士自2019年1月起担任Novan, Inc.的总裁。在她被任命为Novan, Inc.从2017年3月到2019年1月，她担任Novan, Inc.的首席发展官。她一直担任Novan, Inc.的董事（2017年8月以来）。加入Novan之前，她曾在IQVIA Holdings Inc.（生物制药开发服务和商业外包服务的领先跨国供应商）担任各种越来越重要的职务。自1985年以来，她担任临床开发总裁（从2010年到2015年），负责全球所有I-IV期临床开发业务，并在Quintiles执行委员会任职。她还担任Health Decisions的董事，这是一个全面服务合同研究组织，专门从事妇女健康适应症治疗的临床研究。她还担任the Gillings School of Global Public Health at the University of North Carolina, Chapel Hill的公共卫生领导兼职教授。经营着自己的第三方咨询业务。
- Paula Brown Stafford is Novan, Inc. President and Chief Executive Officer and was appointed as Chairman of Novan, Inc. of directors effective July 28 2020. Ms. Stafford has served as Novan, Inc. President since January 2019. Prior to her appointment as Novan, Inc. Chief Executive Officer effective February 2 2020 Ms. Stafford served as our Chief Operating Officer from January 2019 to February 2020 after serving as Novan, Inc. Chief Development Officer from March 2017 to January 2019. Ms. Stafford has served as a member of Novan, Inc. of directors since August 2017. Prior to joining Novan, Ms. Stafford held various roles of increasing importance at Quintiles Transnational Holdings Inc. now IQVIA Holdings Inc., a leading multinational provider of biopharmaceutical development services and commercial outsourcing services, since 1985 including serving as President of Clinical Development from 2010 to 2015 where she was responsible for all Phase I-IV clinical development operations globally and served on the Quintiles Executive Committee. Ms. Stafford also serves as a director of Health Decisions, a full-service contract research organization specializing in clinical studies of therapeutics for women's health indications, serves as an adjunct professor in Public Health Leadership at the Gillings School of Global Public Health at the University of North Carolina, Chapel Hill, and operates her own third-party consulting business.
- Steven D. Skolsky
-
Steven D. Skolsky，自2008年起担任我公司董事；2011年起担任Quintiles Transnational Holdings Inc.和Quintiles Transnational Corp.的高级副总裁兼临床管理主管；2006年至2011年间担任Sequoia Pharmaceuticals Inc.的首席执行官兼总裁；2004年至2006年间担任Trimeris Inc.的首席执行官。他从GlaxoSmithKline跳槽到Trimeris，在前者的20余年任期中担任过多项高级领导职位，包括全球产品战略与临床开发高级副总裁、澳大利亚和新西兰运营经理等。他目前是Fennec Pharmaceuticals Inc.的董事。他获得了查珀尔希尔the University of North Carolina的生物学学士学位。
Steven D. Skolsky has served as a member of Novan, Inc. of directors since March 2 2021. Since January 2010 Mr. Skolsky has served as the founding Principal of Expis Partners, a strategic consulting firm to the biotech, pharmaceutical, life science and clinical services community, with a focused expertise in commercialization, marketing strategy, drug development, operations, strategic planning and corporate and business development. From September 2011 to December 2016 Mr. Skolsky held senior executive roles at Quintiles Transnational Holdings Inc. now IQVIA Holdings Inc., a leading multinational provider of biopharmaceutical development services and commercial outsourcing service, most recently as Senior Vice President & Managing Director and previously, Senior Vice President and Head of Global Clinical Operations. Prior to joining Quintiles, from August 2007 to December 2009 he served as the President and Chief Executive Officer of Sequoia Pharmaceuticals, Inc., and from June 2004 to December 2006 he served as the Chief Executive Officer of Trimeris, Inc. Prior to that, Mr. Skolsky served for more than 20 years at GlaxoSmithKline plc where he held a number of positions including senior leadership roles as Managing Director of GlaxoSmithKline's operations in Australia and New Zealand and Senior Vice President, Global Product Strategy and Clinical Development. - Steven D. Skolsky，自2008年起担任我公司董事；2011年起担任Quintiles Transnational Holdings Inc.和Quintiles Transnational Corp.的高级副总裁兼临床管理主管；2006年至2011年间担任Sequoia Pharmaceuticals Inc.的首席执行官兼总裁；2004年至2006年间担任Trimeris Inc.的首席执行官。他从GlaxoSmithKline跳槽到Trimeris，在前者的20余年任期中担任过多项高级领导职位，包括全球产品战略与临床开发高级副总裁、澳大利亚和新西兰运营经理等。他目前是Fennec Pharmaceuticals Inc.的董事。他获得了查珀尔希尔the University of North Carolina的生物学学士学位。
- Steven D. Skolsky has served as a member of Novan, Inc. of directors since March 2 2021. Since January 2010 Mr. Skolsky has served as the founding Principal of Expis Partners, a strategic consulting firm to the biotech, pharmaceutical, life science and clinical services community, with a focused expertise in commercialization, marketing strategy, drug development, operations, strategic planning and corporate and business development. From September 2011 to December 2016 Mr. Skolsky held senior executive roles at Quintiles Transnational Holdings Inc. now IQVIA Holdings Inc., a leading multinational provider of biopharmaceutical development services and commercial outsourcing service, most recently as Senior Vice President & Managing Director and previously, Senior Vice President and Head of Global Clinical Operations. Prior to joining Quintiles, from August 2007 to December 2009 he served as the President and Chief Executive Officer of Sequoia Pharmaceuticals, Inc., and from June 2004 to December 2006 he served as the Chief Executive Officer of Trimeris, Inc. Prior to that, Mr. Skolsky served for more than 20 years at GlaxoSmithKline plc where he held a number of positions including senior leadership roles as Managing Director of GlaxoSmithKline's operations in Australia and New Zealand and Senior Vice President, Global Product Strategy and Clinical Development.
- W. Kent Geer
-
W. Kent Geer，他担任我们的董事会成员（2015年以来）。他曾是Ernst & Young LLP的审计合伙人（从1989年到2011年）。他曾于2012年开始担任PowerSecure International, Inc（直到2016年5月公司成功出售）的董事会主席。
W. Kent Geer has served as a member of Novan, Inc. of directors since 2015 and as Novan, Inc. Lead Independent Director since June 2017. Since 2016 Mr. Geer has served as managing director, finance and investor relations for Med1 Ventures, LLC, an early-stage medical device development company. Since March 2020 Mr. Geer has served as contract Chief Financial Officer for EternaTear, Inc., an early-stage medical product development company. Mr. Geer was an audit partner with Ernst & Young LLP from 1989 to 2011. Beginning in 2012 Mr. Geer served as the chairman of the board of directors of PowerSecure International, Inc. until the successful sale of the company in May 2016. Mr. Geer also serves on the board of governors of North Raleigh Christian Academy. - W. Kent Geer，他担任我们的董事会成员（2015年以来）。他曾是Ernst & Young LLP的审计合伙人（从1989年到2011年）。他曾于2012年开始担任PowerSecure International, Inc（直到2016年5月公司成功出售）的董事会主席。
- W. Kent Geer has served as a member of Novan, Inc. of directors since 2015 and as Novan, Inc. Lead Independent Director since June 2017. Since 2016 Mr. Geer has served as managing director, finance and investor relations for Med1 Ventures, LLC, an early-stage medical device development company. Since March 2020 Mr. Geer has served as contract Chief Financial Officer for EternaTear, Inc., an early-stage medical product development company. Mr. Geer was an audit partner with Ernst & Young LLP from 1989 to 2011. Beginning in 2012 Mr. Geer served as the chairman of the board of directors of PowerSecure International, Inc. until the successful sale of the company in May 2016. Mr. Geer also serves on the board of governors of North Raleigh Christian Academy.
- John Palmour
-
John Palmour，他担任我们的董事会成员（2010年以来）。1987年以来，他曾任职Cree, Inc.（他共同创办的一家公司），目前担任副总裁兼首席技术官，负责权力和无线电频率。
John Palmour has served as a member of Novan, Inc. of directors since 2010. Since 1987 Dr. Palmour has worked at Cree, Inc., a company he co-founded and for which he currently serves as Vice President and the Chief Technology Officer of the Wolfspeed Division. Dr. Palmour served on Cree’s board of directors from 1995 to 2010. He is currently on the board of directors of Goodzer, Inc., a privately held company focused on local services Internet advertising. - John Palmour，他担任我们的董事会成员（2010年以来）。1987年以来，他曾任职Cree, Inc.（他共同创办的一家公司），目前担任副总裁兼首席技术官，负责权力和无线电频率。
- John Palmour has served as a member of Novan, Inc. of directors since 2010. Since 1987 Dr. Palmour has worked at Cree, Inc., a company he co-founded and for which he currently serves as Vice President and the Chief Technology Officer of the Wolfspeed Division. Dr. Palmour served on Cree’s board of directors from 1995 to 2010. He is currently on the board of directors of Goodzer, Inc., a privately held company focused on local services Internet advertising.
- Machelle Sanders
-
Machelle Sanders 于2017年9月加入Novan, Inc.担任董事，是一位经验丰富的高管，拥有超过29年的进步制药和生物技术经验。桑德斯女士目前担任北卡罗来纳州商务部部长，由州长罗伊·库珀于2021年2月任命。在被任命为北卡罗莱纳州商务部部长之前，Sanders女士于2017年1月被州长Cooper任命为北卡罗莱纳州行政部门部长。在私营部门，她最近负责Biogen, Inc.（一家跨国生物技术公司）的制药运营和技术运营战略，担任质量保证副总裁、制造副总裁和总经理（2009年至2015年）。她也曾担任Biogen, Inc.、Purdue Pharmaceuticals（制药公司）和Diosynth-Akzo Nobel（为制药公司开发和提供活性成分制造流程的公司）的制造、全球质量保证和质量控制的领导职位。她目前任职于Radius Health, Inc.的董事会，这是一家在纳斯达克证券交易所上市的生物制药公司。
Machelle Sanders joined Novan, Inc. of directors in September 2017 and is a seasoned executive with over 29 years of progressive pharmaceutical and biotechnology experience. Ms. Sanders is currently serving as the Secretary of the N.C. Department of Commerce, appointed by Governor Roy Cooper in February 2021. Prior to her appointment as the Secretary of the N.C. Department of Commerce, Ms. Sanders served as Secretary of the N.C. Department of Administration after being appointed by Governor Cooper in January 2017. In the private sector, Ms. Sanders was most recently responsible for the pharmaceutical operations and technology operational strategy at Biogen, Inc., a multinational biotechnology company, as vice president of quality assurance and vice president of manufacturing and general manager from 2009 to 2015. Ms. Sanders has also held leadership positions in manufacturing, global quality assurance and quality control at Biogen, Inc., Purdue Pharmaceuticals, a pharmaceutical company, and Diosynth-Akzo Nobel, a company that develops and offers manufacturing processes for active ingredients for pharmaceutical companies. Ms. Sanders currently serves on the board of directors of Radius Health, Inc., a public biopharmaceutical company listed on the Nasdaq stock exchange. - Machelle Sanders 于2017年9月加入Novan, Inc.担任董事，是一位经验丰富的高管，拥有超过29年的进步制药和生物技术经验。桑德斯女士目前担任北卡罗来纳州商务部部长，由州长罗伊·库珀于2021年2月任命。在被任命为北卡罗莱纳州商务部部长之前，Sanders女士于2017年1月被州长Cooper任命为北卡罗莱纳州行政部门部长。在私营部门，她最近负责Biogen, Inc.（一家跨国生物技术公司）的制药运营和技术运营战略，担任质量保证副总裁、制造副总裁和总经理（2009年至2015年）。她也曾担任Biogen, Inc.、Purdue Pharmaceuticals（制药公司）和Diosynth-Akzo Nobel（为制药公司开发和提供活性成分制造流程的公司）的制造、全球质量保证和质量控制的领导职位。她目前任职于Radius Health, Inc.的董事会，这是一家在纳斯达克证券交易所上市的生物制药公司。
- Machelle Sanders joined Novan, Inc. of directors in September 2017 and is a seasoned executive with over 29 years of progressive pharmaceutical and biotechnology experience. Ms. Sanders is currently serving as the Secretary of the N.C. Department of Commerce, appointed by Governor Roy Cooper in February 2021. Prior to her appointment as the Secretary of the N.C. Department of Commerce, Ms. Sanders served as Secretary of the N.C. Department of Administration after being appointed by Governor Cooper in January 2017. In the private sector, Ms. Sanders was most recently responsible for the pharmaceutical operations and technology operational strategy at Biogen, Inc., a multinational biotechnology company, as vice president of quality assurance and vice president of manufacturing and general manager from 2009 to 2015. Ms. Sanders has also held leadership positions in manufacturing, global quality assurance and quality control at Biogen, Inc., Purdue Pharmaceuticals, a pharmaceutical company, and Diosynth-Akzo Nobel, a company that develops and offers manufacturing processes for active ingredients for pharmaceutical companies. Ms. Sanders currently serves on the board of directors of Radius Health, Inc., a public biopharmaceutical company listed on the Nasdaq stock exchange.
- James L. Bierman
-
James L. Bierman,2014年9月至2015年6月担任Owens & Minor, Inc.（纽约证券交易所代码：OMI）总裁兼首席执行官和董事会成员，该公司是一家财富500强公司，也是医疗和手术用品的主要分销商。此前，他在欧麦斯-麦能医疗担任过多个高级职务，包括2013年8月至2014年9月担任总裁兼首席运营官，2012年3月至2013年8月担任执行副总裁兼首席运营官，2011年4月至2012年3月担任执行副总裁兼首席财务官,2007年6月至2011年4月担任高级副总裁兼首席财务官。在其职业生涯的早期，比尔曼先生曾在Quintiles Transnational Corp.（前纳斯达克：QTRN）担任执行副总裁兼首席财务官。昆泰是为制药、生物技术和医疗器械行业提供产品开发和商业化解决方案的市场领导者。在加入昆泰公司之前，比尔曼曾在1988年至1998年期间担任安达信律师事务所的合伙人。Bierman先生目前担任泰尼特保健公司（纽约证券交易所代码：THC）和Novan, Inc.（纳斯达克：NOVN）的董事会成员。Tenet Healthcare Corporation（纽约证券交易所代码：TERM1）是一家财富500强公司，也是一家多元化的医疗保健服务公司，在美国各地经营着600多家设施、急症医院和门诊中心。Novan，Inc.是一家医学皮肤病公司，主要致力于研究、开发和商业化治疗皮肤病的创新产品。在他担任董事期间，该公司既收购了其皮肤病学平台，又向美国食品药品监督管理局（FDA）提交了首份新药申请（NDA），寻求获得贝达西默凝胶（10.3%）的上市许可，用于局部治疗传染性软疣。比尔曼先生最近担任KL Acquisition公司（前纳斯达克：KLAQU）的独立董事，并担任董事会审计委员会主席。他于2021年1月被任命为董事会成员。该公司是一家注册空白支票公司（SPAC），其业务目的是与一个或多个企业或实体进行合并或类似的业务合并。首次公开发行于2021年1月完成，筹资超过2.5亿美元。该公司没有完成最初的业务合并，并于2022年12月16日通知纳斯达克其赎回、清算和解散的意图。它提交了必要的表格，以便在2022年12月30日之前将该公司的证券摘牌，并允许该公司解除和赎回其所有已发行的公众股票。Bierman先生曾担任Team Health Holdings, Inc.（前纽约证券交易所代码：TMH）董事会的首席独立董事。Team Health是美国向医院和其他医疗保健提供者提供外包医疗保健专业人员和行政服务的最大供应商之一。比尔曼在迪金森学院获得了学士学位，在康奈尔大学约翰逊管理研究生院获得了MBA学位。
James L. Bierman,served as President and Chief Executive Officer of Owens & Minor, Inc., a Fortune 500 company and a leading distributor of medical and surgical supplies, from September 2014 to June 2015.Previously, he served in various other senior roles at Owens & Minor, including President and Chief Operating Officer from August 2013 to September 2014, Executive Vice President and Chief Operating Officer from March 2012 to August 2013, Executive Vice President and Chief Financial Officer from April 2011 to March 2012, and Senior Vice President and Chief Financial Officer from June 2007 to April 2011.From 2001 to 2004, Mr. Bierman served as Executive Vice President and Chief Financial Officer at Quintiles Transnational Corp. Prior to joining Quintiles Transnational, he was a partner at Arthur Andersen LLP.Mr. Bierman earned his B.A. from Dickinson College and his M.B.A. from Cornell University's Johnson Graduate School of Management. - James L. Bierman,2014年9月至2015年6月担任Owens & Minor, Inc.（纽约证券交易所代码：OMI）总裁兼首席执行官和董事会成员，该公司是一家财富500强公司，也是医疗和手术用品的主要分销商。此前，他在欧麦斯-麦能医疗担任过多个高级职务，包括2013年8月至2014年9月担任总裁兼首席运营官，2012年3月至2013年8月担任执行副总裁兼首席运营官，2011年4月至2012年3月担任执行副总裁兼首席财务官,2007年6月至2011年4月担任高级副总裁兼首席财务官。在其职业生涯的早期，比尔曼先生曾在Quintiles Transnational Corp.（前纳斯达克：QTRN）担任执行副总裁兼首席财务官。昆泰是为制药、生物技术和医疗器械行业提供产品开发和商业化解决方案的市场领导者。在加入昆泰公司之前，比尔曼曾在1988年至1998年期间担任安达信律师事务所的合伙人。Bierman先生目前担任泰尼特保健公司（纽约证券交易所代码：THC）和Novan, Inc.（纳斯达克：NOVN）的董事会成员。Tenet Healthcare Corporation（纽约证券交易所代码：TERM1）是一家财富500强公司，也是一家多元化的医疗保健服务公司，在美国各地经营着600多家设施、急症医院和门诊中心。Novan，Inc.是一家医学皮肤病公司，主要致力于研究、开发和商业化治疗皮肤病的创新产品。在他担任董事期间，该公司既收购了其皮肤病学平台，又向美国食品药品监督管理局（FDA）提交了首份新药申请（NDA），寻求获得贝达西默凝胶（10.3%）的上市许可，用于局部治疗传染性软疣。比尔曼先生最近担任KL Acquisition公司（前纳斯达克：KLAQU）的独立董事，并担任董事会审计委员会主席。他于2021年1月被任命为董事会成员。该公司是一家注册空白支票公司（SPAC），其业务目的是与一个或多个企业或实体进行合并或类似的业务合并。首次公开发行于2021年1月完成，筹资超过2.5亿美元。该公司没有完成最初的业务合并，并于2022年12月16日通知纳斯达克其赎回、清算和解散的意图。它提交了必要的表格，以便在2022年12月30日之前将该公司的证券摘牌，并允许该公司解除和赎回其所有已发行的公众股票。Bierman先生曾担任Team Health Holdings, Inc.（前纽约证券交易所代码：TMH）董事会的首席独立董事。Team Health是美国向医院和其他医疗保健提供者提供外包医疗保健专业人员和行政服务的最大供应商之一。比尔曼在迪金森学院获得了学士学位，在康奈尔大学约翰逊管理研究生院获得了MBA学位。
- James L. Bierman,served as President and Chief Executive Officer of Owens & Minor, Inc., a Fortune 500 company and a leading distributor of medical and surgical supplies, from September 2014 to June 2015.Previously, he served in various other senior roles at Owens & Minor, including President and Chief Operating Officer from August 2013 to September 2014, Executive Vice President and Chief Operating Officer from March 2012 to August 2013, Executive Vice President and Chief Financial Officer from April 2011 to March 2012, and Senior Vice President and Chief Financial Officer from June 2007 to April 2011.From 2001 to 2004, Mr. Bierman served as Executive Vice President and Chief Financial Officer at Quintiles Transnational Corp. Prior to joining Quintiles Transnational, he was a partner at Arthur Andersen LLP.Mr. Bierman earned his B.A. from Dickinson College and his M.B.A. from Cornell University's Johnson Graduate School of Management.
- James L. Bierman
-
James L. Bierman，他担任我们的董事（2010年8月以来）。他是Owens & Minor公司（财富500强公司，一家医疗和外科物资的主要经销商）的总裁兼首席营运官（2013年8月以来）。此前，他曾担任Owens & Minor公司的执行副总裁兼首席运营官（从2012年3月到2013年8月）、执行副总裁兼首席财务官（从2011年4月到2012年3月）、高级副总裁兼首席财务官（从2007年6月到2011年4月）。从2001年到2004年，他担任Quintiles Transnational公司的执行副总裁兼首席财务官。他是Quintiles Transnational公司和Pharma Services Holding公司（总公司）的前任董事。加入Quintiles Transnational公司之前，他曾担任Arthur Andersen公司的合伙人（从1988年到1998年）。他持有Cornell University’s Johnson Graduate School of Management的工商管理硕士学位，以及Dickinson College的学士学位。
James L. Bierman was appointed to Novan, Inc. of directors on September 23 2020 in connection with Novan, Inc. of director‘s vote to increase of the size of our board of directors from six to seven directors. Mr. Bierman served as President and Chief Executive Officer and as a member of the board of directors of Owens & Minor, Inc., a Fortune 500 company and a leading distributor of medical and surgical supplies, from September 2014 to June 2015. Previously, he served in various other senior roles at Owens & Minor, including President and Chief Operating Officer from August 2013 to September 2014 Executive Vice President and Chief Operating Officer from March 2012 to August 2013 Executive Vice President and Chief Financial Officer from April 2011 to March 2012 and Senior Vice President and Chief Financial Officer from June 2007 to April 2011. Earlier in his career, Mr. Bierman served as Executive Vice President and Chief Financial Officer at Quintiles Transnational Corp. now IQVIA Holdings Inc.. Before joining Quintiles, Mr. Bierman was a partner with Arthur Andersen LLP from 1988 to 1998. Mr. Bierman currently serves on the board of directors of Tenet Healthcare Corporation, a public healthcare services companies listed on the New York Stock Exchange, MiMedX Group, Inc., a public biomedical company listed on the Nasdaq stock exchange, and KL Acquisition Corp., a special purpose acquisition company listed on the Nasdaq stock exchange, and previously served as Independent Lead Director on the board of directors of Team Health Holdings, Inc. - James L. Bierman，他担任我们的董事（2010年8月以来）。他是Owens & Minor公司（财富500强公司，一家医疗和外科物资的主要经销商）的总裁兼首席营运官（2013年8月以来）。此前，他曾担任Owens & Minor公司的执行副总裁兼首席运营官（从2012年3月到2013年8月）、执行副总裁兼首席财务官（从2011年4月到2012年3月）、高级副总裁兼首席财务官（从2007年6月到2011年4月）。从2001年到2004年，他担任Quintiles Transnational公司的执行副总裁兼首席财务官。他是Quintiles Transnational公司和Pharma Services Holding公司（总公司）的前任董事。加入Quintiles Transnational公司之前，他曾担任Arthur Andersen公司的合伙人（从1988年到1998年）。他持有Cornell University’s Johnson Graduate School of Management的工商管理硕士学位，以及Dickinson College的学士学位。
- James L. Bierman was appointed to Novan, Inc. of directors on September 23 2020 in connection with Novan, Inc. of director‘s vote to increase of the size of our board of directors from six to seven directors. Mr. Bierman served as President and Chief Executive Officer and as a member of the board of directors of Owens & Minor, Inc., a Fortune 500 company and a leading distributor of medical and surgical supplies, from September 2014 to June 2015. Previously, he served in various other senior roles at Owens & Minor, including President and Chief Operating Officer from August 2013 to September 2014 Executive Vice President and Chief Operating Officer from March 2012 to August 2013 Executive Vice President and Chief Financial Officer from April 2011 to March 2012 and Senior Vice President and Chief Financial Officer from June 2007 to April 2011. Earlier in his career, Mr. Bierman served as Executive Vice President and Chief Financial Officer at Quintiles Transnational Corp. now IQVIA Holdings Inc.. Before joining Quintiles, Mr. Bierman was a partner with Arthur Andersen LLP from 1988 to 1998. Mr. Bierman currently serves on the board of directors of Tenet Healthcare Corporation, a public healthcare services companies listed on the New York Stock Exchange, MiMedX Group, Inc., a public biomedical company listed on the Nasdaq stock exchange, and KL Acquisition Corp., a special purpose acquisition company listed on the Nasdaq stock exchange, and previously served as Independent Lead Director on the board of directors of Team Health Holdings, Inc.
- Robert J. Keegan
-
Robert J. Keegan， 退休之前，他从2000年起开始担任古德伊尔轮胎和橡胶公司总裁和董事；2003年到2010年担任公司董事长。2000年加入古德伊尔并担任多个领导职位，包括首席运营官。他从1997年到2000年担任伊士曼柯达公司执行副总裁；从1972年到2000年他在伊士曼柯达公司市场、金融以及管理方面担任多个职位，除去1995年到1997年他在艾利丹尼森公司担任执行副总裁。他是施乐公司审计委员会和薪酬委员会成员。
Robert J. Keegan has served as a member of Novan, Inc. of directors since 2016. Mr. Keegan held the roles of Chief Executive Officer and chairman of the board of directors of Goodyear Tire and Rubber Co. from 2003 to 2010. Most recently, he served as the non-executive chairman of the board of directors of Xerox Corporation and was an operating partner of the San Francisco-based private equity firm Friedman, Fleischer & Lowe. From 1972 to 2000 Mr. Keegan held various marketing, financial and managerial posts at Eastman Kodak, except for a two-year period from 1995 to 1997 when he worked as an executive vice president of the Avery Dennison Corporation. Mr. Keegan serves on the board of directors of the Heart Center of Duke University and the Duke Health Board of Visitors. Mr. Keegan is a partner of L&K Properties of North Carolina, LLC. - Robert J. Keegan， 退休之前，他从2000年起开始担任古德伊尔轮胎和橡胶公司总裁和董事；2003年到2010年担任公司董事长。2000年加入古德伊尔并担任多个领导职位，包括首席运营官。他从1997年到2000年担任伊士曼柯达公司执行副总裁；从1972年到2000年他在伊士曼柯达公司市场、金融以及管理方面担任多个职位，除去1995年到1997年他在艾利丹尼森公司担任执行副总裁。他是施乐公司审计委员会和薪酬委员会成员。
- Robert J. Keegan has served as a member of Novan, Inc. of directors since 2016. Mr. Keegan held the roles of Chief Executive Officer and chairman of the board of directors of Goodyear Tire and Rubber Co. from 2003 to 2010. Most recently, he served as the non-executive chairman of the board of directors of Xerox Corporation and was an operating partner of the San Francisco-based private equity firm Friedman, Fleischer & Lowe. From 1972 to 2000 Mr. Keegan held various marketing, financial and managerial posts at Eastman Kodak, except for a two-year period from 1995 to 1997 when he worked as an executive vice president of the Avery Dennison Corporation. Mr. Keegan serves on the board of directors of the Heart Center of Duke University and the Duke Health Board of Visitors. Mr. Keegan is a partner of L&K Properties of North Carolina, LLC.
- W. Kent Geer
-
W. Kent Geer，他担任Novan, Inc.的董事会成员（2015年以来）。从2012年6月开始担任Powersecure International, Inc.董事，包括从2013年6月开始担任Powersecure International, Inc.董事会主席。Geer先生还担任提名与公司治理委员会主席，并担任其他董事委员会的委员。从1977年到2011年，Geer先生供职于安永会计师事务所（Ernst & Young LLP）的审计执业部，包括从1989年开始担任合伙人。在安永会计师事务所任职期间，他担任不同行业的大量公众与私人公司的首席审计合伙人，包括通信、软件、生物技术、半导体、分销与多个其他产品与服务公司。他担任安永会计师事务所北卡罗来州罗利市的企业家服务事业部的审计执业主管，担任南北卡罗莱纳州地区的技术行业执业部市场团队主管，并担任南北卡罗莱纳州的安永会计师事务所的年度企业家项目的合伙人。Geer先生还担任一家私人所有的媒体公司的顾问委员会委员，以及一家非盈利教育机构的理事会理事。
W. Kent Geer has served on our Board of Directors since June 2012 including as our Chairman of the Board since June 2013. Mr. Geer also serves as the Chairman of the Nominating and Corporate Governance Committee and as a member of the other Board committees. Mr. Geer served in the audit practice of Ernst & Young LLP from 1977 until 2011 including as a partner since 1989. During his career at Ernst & Young, he served as lead audit partner for a large number of public and private companies in different industries including telecommunications, software, biotechnology, semi-conductors, distribution and various other product and service companies. He served as audit practice leader for the Ernst & Young Entrepreneurial Services Group in Raleigh, North Carolina, the market team leader for the technology industry practice of the Carolinas area, and the partner in charge for the Carolinas' Ernst & Young Entrepreneur of the Year program. Mr. Geer also serves on the advisory board of a privately-held media company and the board of governors of a non-profit educational institution. - W. Kent Geer，他担任Novan, Inc.的董事会成员（2015年以来）。从2012年6月开始担任Powersecure International, Inc.董事，包括从2013年6月开始担任Powersecure International, Inc.董事会主席。Geer先生还担任提名与公司治理委员会主席，并担任其他董事委员会的委员。从1977年到2011年，Geer先生供职于安永会计师事务所（Ernst & Young LLP）的审计执业部，包括从1989年开始担任合伙人。在安永会计师事务所任职期间，他担任不同行业的大量公众与私人公司的首席审计合伙人，包括通信、软件、生物技术、半导体、分销与多个其他产品与服务公司。他担任安永会计师事务所北卡罗来州罗利市的企业家服务事业部的审计执业主管，担任南北卡罗莱纳州地区的技术行业执业部市场团队主管，并担任南北卡罗莱纳州的安永会计师事务所的年度企业家项目的合伙人。Geer先生还担任一家私人所有的媒体公司的顾问委员会委员，以及一家非盈利教育机构的理事会理事。
- W. Kent Geer has served on our Board of Directors since June 2012 including as our Chairman of the Board since June 2013. Mr. Geer also serves as the Chairman of the Nominating and Corporate Governance Committee and as a member of the other Board committees. Mr. Geer served in the audit practice of Ernst & Young LLP from 1977 until 2011 including as a partner since 1989. During his career at Ernst & Young, he served as lead audit partner for a large number of public and private companies in different industries including telecommunications, software, biotechnology, semi-conductors, distribution and various other product and service companies. He served as audit practice leader for the Ernst & Young Entrepreneurial Services Group in Raleigh, North Carolina, the market team leader for the technology industry practice of the Carolinas area, and the partner in charge for the Carolinas' Ernst & Young Entrepreneur of the Year program. Mr. Geer also serves on the advisory board of a privately-held media company and the board of governors of a non-profit educational institution.
高管简历
中英对照 | 中文 | 英文- Paula Brown Stafford
Paula Brown Stafford，她是Novan, Inc.的总裁兼首席执行官，并于2020年7月28日被任命为董事长。Stafford女士自2019年1月起担任Novan, Inc.的总裁。在她被任命为Novan, Inc.从2017年3月到2019年1月，她担任Novan, Inc.的首席发展官。她一直担任Novan, Inc.的董事（2017年8月以来）。加入Novan之前，她曾在IQVIA Holdings Inc.（生物制药开发服务和商业外包服务的领先跨国供应商）担任各种越来越重要的职务。自1985年以来，她担任临床开发总裁（从2010年到2015年），负责全球所有I-IV期临床开发业务，并在Quintiles执行委员会任职。她还担任Health Decisions的董事，这是一个全面服务合同研究组织，专门从事妇女健康适应症治疗的临床研究。她还担任the Gillings School of Global Public Health at the University of North Carolina, Chapel Hill的公共卫生领导兼职教授。经营着自己的第三方咨询业务。
Paula Brown Stafford is Novan, Inc. President and Chief Executive Officer and was appointed as Chairman of Novan, Inc. of directors effective July 28 2020. Ms. Stafford has served as Novan, Inc. President since January 2019. Prior to her appointment as Novan, Inc. Chief Executive Officer effective February 2 2020 Ms. Stafford served as our Chief Operating Officer from January 2019 to February 2020 after serving as Novan, Inc. Chief Development Officer from March 2017 to January 2019. Ms. Stafford has served as a member of Novan, Inc. of directors since August 2017. Prior to joining Novan, Ms. Stafford held various roles of increasing importance at Quintiles Transnational Holdings Inc. now IQVIA Holdings Inc., a leading multinational provider of biopharmaceutical development services and commercial outsourcing services, since 1985 including serving as President of Clinical Development from 2010 to 2015 where she was responsible for all Phase I-IV clinical development operations globally and served on the Quintiles Executive Committee. Ms. Stafford also serves as a director of Health Decisions, a full-service contract research organization specializing in clinical studies of therapeutics for women's health indications, serves as an adjunct professor in Public Health Leadership at the Gillings School of Global Public Health at the University of North Carolina, Chapel Hill, and operates her own third-party consulting business.- Paula Brown Stafford，她是Novan, Inc.的总裁兼首席执行官，并于2020年7月28日被任命为董事长。Stafford女士自2019年1月起担任Novan, Inc.的总裁。在她被任命为Novan, Inc.从2017年3月到2019年1月，她担任Novan, Inc.的首席发展官。她一直担任Novan, Inc.的董事（2017年8月以来）。加入Novan之前，她曾在IQVIA Holdings Inc.（生物制药开发服务和商业外包服务的领先跨国供应商）担任各种越来越重要的职务。自1985年以来，她担任临床开发总裁（从2010年到2015年），负责全球所有I-IV期临床开发业务，并在Quintiles执行委员会任职。她还担任Health Decisions的董事，这是一个全面服务合同研究组织，专门从事妇女健康适应症治疗的临床研究。她还担任the Gillings School of Global Public Health at the University of North Carolina, Chapel Hill的公共卫生领导兼职教授。经营着自己的第三方咨询业务。
- Paula Brown Stafford is Novan, Inc. President and Chief Executive Officer and was appointed as Chairman of Novan, Inc. of directors effective July 28 2020. Ms. Stafford has served as Novan, Inc. President since January 2019. Prior to her appointment as Novan, Inc. Chief Executive Officer effective February 2 2020 Ms. Stafford served as our Chief Operating Officer from January 2019 to February 2020 after serving as Novan, Inc. Chief Development Officer from March 2017 to January 2019. Ms. Stafford has served as a member of Novan, Inc. of directors since August 2017. Prior to joining Novan, Ms. Stafford held various roles of increasing importance at Quintiles Transnational Holdings Inc. now IQVIA Holdings Inc., a leading multinational provider of biopharmaceutical development services and commercial outsourcing services, since 1985 including serving as President of Clinical Development from 2010 to 2015 where she was responsible for all Phase I-IV clinical development operations globally and served on the Quintiles Executive Committee. Ms. Stafford also serves as a director of Health Decisions, a full-service contract research organization specializing in clinical studies of therapeutics for women's health indications, serves as an adjunct professor in Public Health Leadership at the Gillings School of Global Public Health at the University of North Carolina, Chapel Hill, and operates her own third-party consulting business.
- John M. Gay
John M. Gay被任命为Novan, Inc.自2020年9月23日起担任首席财务官，并担任Novan, Inc.的首席财务官和公司秘书。他于2018年5月加入Novan，此前曾担任财务高级总监和公司总监（至2019年1月），以及财务和公司总监副总裁（至2020年9月23日）。从2014年5月到2018年4月，他担任Valassis Digital Corp.和MaxPoint Inc.的SEC报告董事。同性恋先生还担任Furiex制药公司控制器，Inc .）从2010年6月到2014年5月，包括从最初在纳斯达克股票交易所上市通过一项协议的执行提供由森林实验室公司的收购，Inc .)的子公司Actavis公司，这是一笔价值约11亿美元的全现金交易。加入Furiex Pharmaceuticals, Inc.之前，2000年9月至2010年5月，他曾担任Deloitte和Arthur Andersen的审计高级经理和其他职责，并不断增加。他是一名注册会计师，持有北卡罗来纳大学教堂山分校（the University of North Carolina at Chapel Hill）的经济学和历史学学士学位和会计硕士学位。
John M. Gay was appointed as Novan, Inc. Chief Financial Officer effective September 23 2020 and also serves as Novan, Inc. principal financial officer and Corporate Secretary. He joined Novan in May of 2018 and previously held the position of Senior Director of Finance and Corporate Controller through January 2019 and Vice President, Finance and Corporate Controller from January 2019 until September 23 2020. Prior to Novan, Mr. Gay held previous director positions, including Director of SEC Reporting, with Valassis Digital Corp. and MaxPoint Inc., from May 2014 to April 2018. Mr. Gay also served as Corporate Controller of Furiex Pharmaceuticals, Inc. from June 2010 to May 2014 including from its initial listing on the Nasdaq stock exchange through the execution of an agreement providing for the acquisition of the company by Forest Laboratories, Inc., a subsidiary of Actavis plc, in an all-cash transaction valued at approximately $1.1 billion. Prior to joining Furiex Pharmaceuticals, Inc., Mr. Gay served as Audit Senior Manager and in other roles of increasing responsibilities at Deloitte and Arthur Andersen from September 2000 to May 2010. Mr. Gay is a certified public accountant and holds Bachelor's degrees in Economics and History, and a Master of Accounting degree from the University of North Carolina at Chapel Hill.- John M. Gay被任命为Novan, Inc.自2020年9月23日起担任首席财务官，并担任Novan, Inc.的首席财务官和公司秘书。他于2018年5月加入Novan，此前曾担任财务高级总监和公司总监（至2019年1月），以及财务和公司总监副总裁（至2020年9月23日）。从2014年5月到2018年4月，他担任Valassis Digital Corp.和MaxPoint Inc.的SEC报告董事。同性恋先生还担任Furiex制药公司控制器，Inc .）从2010年6月到2014年5月，包括从最初在纳斯达克股票交易所上市通过一项协议的执行提供由森林实验室公司的收购，Inc .)的子公司Actavis公司，这是一笔价值约11亿美元的全现金交易。加入Furiex Pharmaceuticals, Inc.之前，2000年9月至2010年5月，他曾担任Deloitte和Arthur Andersen的审计高级经理和其他职责，并不断增加。他是一名注册会计师，持有北卡罗来纳大学教堂山分校（the University of North Carolina at Chapel Hill）的经济学和历史学学士学位和会计硕士学位。
- John M. Gay was appointed as Novan, Inc. Chief Financial Officer effective September 23 2020 and also serves as Novan, Inc. principal financial officer and Corporate Secretary. He joined Novan in May of 2018 and previously held the position of Senior Director of Finance and Corporate Controller through January 2019 and Vice President, Finance and Corporate Controller from January 2019 until September 23 2020. Prior to Novan, Mr. Gay held previous director positions, including Director of SEC Reporting, with Valassis Digital Corp. and MaxPoint Inc., from May 2014 to April 2018. Mr. Gay also served as Corporate Controller of Furiex Pharmaceuticals, Inc. from June 2010 to May 2014 including from its initial listing on the Nasdaq stock exchange through the execution of an agreement providing for the acquisition of the company by Forest Laboratories, Inc., a subsidiary of Actavis plc, in an all-cash transaction valued at approximately $1.1 billion. Prior to joining Furiex Pharmaceuticals, Inc., Mr. Gay served as Audit Senior Manager and in other roles of increasing responsibilities at Deloitte and Arthur Andersen from September 2000 to May 2010. Mr. Gay is a certified public accountant and holds Bachelor's degrees in Economics and History, and a Master of Accounting degree from the University of North Carolina at Chapel Hill.